000168130 001__ 168130
000168130 005__ 20240229133558.0
000168130 0247_ $$2doi$$a10.1093/ije/dyab032
000168130 0247_ $$2pmid$$apmid:33755122
000168130 0247_ $$2ISSN$$a0300-5771
000168130 0247_ $$2ISSN$$a1464-3685
000168130 0247_ $$2altmetric$$aaltmetric:102691599
000168130 037__ $$aDKFZ-2021-00698
000168130 041__ $$aEnglish
000168130 082__ $$a610
000168130 1001_ $$aEllingjord-Dale, Merete$$b0
000168130 245__ $$aLong-term weight change and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
000168130 260__ $$aOxford$$bOxford Univ. Press$$c2021
000168130 3367_ $$2DRIVER$$aarticle
000168130 3367_ $$2DataCite$$aOutput Types/Journal article
000168130 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642519250_12953
000168130 3367_ $$2BibTeX$$aARTICLE
000168130 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168130 3367_ $$00$$2EndNote$$aJournal Article
000168130 500__ $$aVolume 50, Issue 6, December 2021, Pages 1914–1926
000168130 520__ $$aThe role of obesity and weight change in breast-cancer development is complex and incompletely understood. We investigated long-term weight change and breast-cancer risk by body mass index (BMI) at age 20 years, menopausal status, hormone replacement therapy (HRT) and hormone-receptor status.Using data on weight collected at three different time points from women who participated in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, we investigated the association between weight change from age 20 years until middle adulthood and risk of breast cancer.In total, 150 257 women with a median age of 51 years at cohort entry were followed for an average of 14 years (standard deviation = 3.9) during which 6532 breast-cancer cases occurred. Compared with women with stable weight (±2.5 kg), long-term weight gain >10 kg was positively associated with postmenopausal breast-cancer risk in women who were lean at age 20 [hazard ratio (HR) = 1.42; 95% confidence interval 1.22-1.65] in ever HRT users (HR = 1.23; 1.04-1.44), in never HRT users (HR = 1.40; 1.16-1.68) and in oestrogen-and-progesterone-receptor-positive (ER+PR+) breast cancer (HR = 1.46; 1.15-1.85).Long-term weight gain was positively associated with postmenopausal breast cancer in women who were lean at age 20, both in HRT ever users and non-users, and hormone-receptor-positive breast cancer.
000168130 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000168130 588__ $$aDataset connected to CrossRef, PubMed,
000168130 650_7 $$2Other$$abreast cancer
000168130 650_7 $$2Other$$acohort study
000168130 650_7 $$2Other$$along-term weight change
000168130 7001_ $$aChristakoudi, Sofia$$b1
000168130 7001_ $$aWeiderpass, Elisabete$$b2
000168130 7001_ $$aPanico, Salvatore$$b3
000168130 7001_ $$aDossus, Laure$$b4
000168130 7001_ $$aOlsen, Anja$$b5
000168130 7001_ $$aTjønneland, Anne$$b6
000168130 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b7$$udkfz
000168130 7001_ $$aSchulze, Matthias B$$b8
000168130 7001_ $$aMasala, Giovanna$$b9
000168130 7001_ $$aGram, Inger T$$b10
000168130 7001_ $$aSkeie, Guri$$b11
000168130 7001_ $$aRosendahl, Ann H$$b12
000168130 7001_ $$aSund, Malin$$b13
000168130 7001_ $$aKey, Tim$$b14
000168130 7001_ $$aFerrari, Pietro$$b15
000168130 7001_ $$aGunter, Marc$$b16
000168130 7001_ $$aHeath, Alicia K$$b17
000168130 7001_ $$aTsilidis, Konstantinos K$$b18
000168130 7001_ $$aRiboli, Elio$$b19
000168130 7001_ $$aAuthors, Additional$$b20$$eCollaboration Author
000168130 773__ $$0PERI:(DE-600)1494592-7$$a10.1093/ije/dyab032$$gp. dyab032$$n6$$p1914–1926$$tInternational journal of epidemiology$$v50$$x1464-3685$$y2021
000168130 909CO $$ooai:inrepo02.dkfz.de:168130$$pVDB
000168130 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000168130 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000168130 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000168130 9141_ $$y2021
000168130 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-02-04$$wger
000168130 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J EPIDEMIOL : 2019$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-04
000168130 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J EPIDEMIOL : 2019$$d2021-02-04
000168130 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000168130 980__ $$ajournal
000168130 980__ $$aVDB
000168130 980__ $$aI:(DE-He78)C020-20160331
000168130 980__ $$aUNRESTRICTED